Search

Your search keyword '"Javier Ruiz Guiñazú"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Javier Ruiz Guiñazú" Remove constraint Author: "Javier Ruiz Guiñazú" Search Limiters Full Text Remove constraint Search Limiters: Full Text
24 results on '"Javier Ruiz Guiñazú"'

Search Results

1. Correction: Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial.

2. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.

3. Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial

4. Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans

5. Development of patient- and observer-reported outcome measures to assess COVID-19 signs and symptoms in children and adolescents

6. Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience

7. Quantifying Antibody Persistence After a Single Dose of <scp>COVID</scp> ‐19 Vaccine Ad26. <scp>COV2</scp> .S in Humans Using a Mechanistic Modeling and Simulation Approach

8. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage

9. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children – A randomized controlled trial

10. Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial

11. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

12. Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa

13. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

14. Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials

15. Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial

16. Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study

17. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage

18. Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial

19. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children – A randomized controlled trial

20. 119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated

21. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study

22. Abstracts from the 8th International Congress of the Asia Pacific Society of Infection Control (APSIC)

23. Immunogenicity of a 2 + 1 Infant Vaccination Series with 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV): a Randomized Trial Exploring Interchangeability of PCVs

24. Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status

Catalog

Books, media, physical & digital resources